Deborah J. Andrews - 29 Jun 2021 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director
Signature
/s/ Grant Harbert, as Attorney-in-Fact
Issuer symbol
LCTX
Transactions as of
29 Jun 2021
Net transactions value
-$1,702
Form type
4
Filing time
30 Jun 2021, 19:01:17 UTC
Next filing
01 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares, no par value Options Exercise $54,384 +24,720 +247% $2.20 34,720 29 Jun 2021 Direct
transaction LCTX Common Shares, no par value Sale $56,086 -19,142 -55% $2.93 15,578 29 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Stock Option (right to buy) Options Exercise $0 -24,720 -100% $0.000000* 0 29 Jun 2021 Common Shares 24,720 $2.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average. These shares were sold in multiple transactions at a price of $2.93 or $2.935. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2 This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016

Remarks:

Exhibit 24.1 - Substitute Power of Attorney